Add listing
    0
    Add listing

    Alentis Therapeutics AG Verified listing

    • Swiss Biotech Association
      Member

    Alentis develops breakthrough treatments for fibrotic diseases. The pipeline includes specific antibodies against Claudin-1, a novel target in fibrosis and cancer. Unlike most therapies Alentis’ approach aims at a direct reversal of disease progression.

    Location
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2019
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in